Literature DB >> 6116660

Hepatic and extrahepatic glucuronidation of lorazepam in the dog.

J F Gerkens, P V Desmond, S Schenker, R A Branch.   

Abstract

The pharmacokinetic disposition of lorazepam was investigated in sham-operated aneshetized dogs, dogs with hepatic devascularization, and dogs with total splanchnic devascularization following i.v. administration of 0.3 mg per kg of the drug. In sham-operated dogs, lorazepam distribution was extensive (100 +/- 15.2 liters) and clearance approximately expected liver blood flow (971 +/- 91 ml per min). Lorazepam glucuronide levels in plasma rose rapidly in the first hour and reached a plateau by 5 hr. Urinary recovery of the conjugate in 5 hr was 45% of administered dose. Hepatic devascularization resulted in 39% reduction in distribution volume, and 89% reduction in clearance; however, there was still 105 +/- 88 ml per min of extrahepatic lorazepam clearance. Five-hour urinary recovery of conjugate decreased by 80%. Total splanchnic devascularization resulted in 37% further reduction in extrahepatic clearance, almost complete inhibition of urinary recovery of conjugate, and further reduction in the volume of distribution. It is concluded that the liver is the major site for lorazepam metabolism in dogs; however, appreciable extrahepatic metabolism occurs, partly in nonhepatic components of the splanchnic organs which act as a reservoir during drug distribution.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6116660     DOI: 10.1002/hep.1840010409

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  3 in total

1.  The pharmacokinetics of midazolam following orthotopic liver transplantation.

Authors:  M P Shelly; J S Dixon; G R Park
Journal:  Br J Clin Pharmacol       Date:  1989-05       Impact factor: 4.335

Review 2.  Individual variation in first-pass metabolism.

Authors:  Y K Tam
Journal:  Clin Pharmacokinet       Date:  1993-10       Impact factor: 6.447

3.  The effects of age and chronic liver disease on the elimination of temazepam.

Authors:  H Ghabrial; P V Desmond; K J Watson; A J Gijsbers; P J Harman; K J Breen; M L Mashford
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.